Ongoing Assessments & Recent Research.
Easy access to our work
Alzheimer’s Disease
Mar 2023Amyotrophic Lateral Sclerosis (ALS)
Aug 2022Hemophilia A and B
Nov 2022Obesity Management
Sep 2022Menopause: Vasomotor Symptoms
Dec 2022Our Origin Story.
ICER President Dr. Steve Pearson explains why he founded an organization to advance the use of evidence to improve health care affordability and access for all patients and their families.
Featured News & Insights.
Learn about our latest work.
ICER Releases Draft Evidence Report on Gene Therapies for Hemophilia A and B
Public comment period now open until October 11, 2022; Requests to make oral comment during public meeting also being accepted.
09/13/2022ICER Publishes Final Evidence Report and Policy Recommendations on Treatments for Amyotrophic Lateral Sclerosis
Majority of independent appraisal committee voted that evidence is adequate to demonstrate that both AMX0035 and oral edaravone (in population narrower than its label) provide a net health benefit compared to standard of care; also determined that at current pricing or price estimates both therapies represent a “low” long-term value for money.
09/13/2022ICER Publishes Evidence Report on Treatments for Obesity Management
Greater weight loss was seen with semaglutide and with phentermine/topiramate; less weight loss was seen with liraglutide and with bupropion/naltrexone.
08/31/2022The ICER Impact.
New York Medicaid pursued discounts, many of which were in line with ICER reports, which have saved the state over $500 million
Engaged with over 300 patient groups and patient reps
In a landmark international program, HTA agencies around the world can now access ICER’s customizable COVID-19 Cost-Effectiveness Model
Latest
Developments.
We recently celebrated our 15th anniversary! Learn more.
Dr. Melanie Whittington, ICER’s Director of Health Economics, received the Bernie O’Brien New Investigator Award, which recognizes those who have shown evidence of exceptional promise based on their emerging body of technical and scholarly work in the field of health economics. Learn more.
Listen to our podcast, “A Prescription for Fair Pricing“. Subscribe now on Apple, Google, or Spotify.
Current
Policy Papers.
Easy access to our ongoing policy papers
Barriers to Fair Access
First-ever scorecard of several key appropriate access criteria reveals variation across largest payers but high concordance for clinical eligibility criteria, step therapy, and provider restrictions; lower concordance found for formulary tiering criteria.
Unsupported Price Increases
Out of 10 identified drugs that had substantial 2020 price increases net of rebates on top of already high current spending, seven were not supported by new clinical evidence; net price increases on these seven drugs cost Americans an additional $1.67 billion in annual drug spend, of which nearly $1.4 billion was due to a single drug alone: Humira.
Evaluating and Advancing Health Technology Assessment Methods that Support Health Equity
ICER received a new grant from The Commonwealth Fund to evaluate procedural and methodological changes that could further support health equity goals in health technology assessment (HTA). The findings from this effort will guide ICER’s update to its value assessment framework and inform the work of other HTA groups worldwide.